[Back to Issue 10 ToC] [Back to Journal Contents] [Back to Biochemistry (Moscow) Home page]

Induction of Tumor-Associated Phenotype in Normal Fibroblasts by Glioma Cell Apoptotic Bodies


Kseniya V. Kovalskaya1, Matvei M. Titov2, Konstantin K. Baskaev1, Aleksei Y. Lupatov1, Darya M. Potashnikova3, Olga Y. Susova4, Yan S. Kim1, Konstantin N. Yarygin1,5, Roman V. Kholodenko2, and Irina V. Kholodenko1,a*

1Institute of Biomedical Chemistry, 119121 Moscow, Russia

2Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia

3Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia

4Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia

5Russian Medical Academy of Continuous Professional Education, 125993 Moscow, Russia

* To whom correspondence should be addressed.

Received: August 16, 2025; Revised: October 6, 2025; Accepted: October 8, 2025
Tumor-associated fibroblasts (TAFs) are a key cellular component of solid tumors, including gliomas. They support the growth of malignant cells, stimulate their invasion and metastasis, induce chemoresistance, and suppress the antitumor immune response. TAFs are formed from resident stromal cells under the influence of tumor cell secretome, including growth factors, chemokines, and extracellular vesicles. Communication between malignant cells and TAFs occurs through direct cell–cell contacts and exchange of secreted molecules and membrane vesicles. In this work, apoptotic bodies (apoBDs) were obtained from two types of glioma cells (T98g cell line and Gbl25 cells isolated from a glioblastoma biopsy) and characterized for surface markers. The surface of tumor apoBDs contained glioblastoma tumor-associated markers, such as GD2 ganglioside and A2B5 antigen. Glioma apoBDs contained lower levels of “don’t eat me” molecules and higher levels of “eat me” molecules compared to the original intact glioma cells. On one hand, glioma apoBDs reduced the viability of normal dermal fibroblasts in a dose-dependent manner; on the other hand, they initiated their transformation into the inflammatory subtype of TAFs (iTAFs). iTAFs obtained in this way demonstrated upregulated transcription of genes encoding cytokines, chemokines, and growth factors (IL17A, IL18, IL33, IFN-γ, CCL3, CCL5, CXCL1, CXCL5, CXCL10, CXCL12, TGFB1, and TNF) responsible for maintaining both tumorigenesis itself and the ability of fibroblasts to support it. It was found that glioma apoBDs were able to transfer tumor-associated markers (GD2 ganglioside and A2B5 antigen) to normal fibroblasts. The assessment of the effects of anti-GD2 antibody–drug conjugates (ADCs) on TAFs suggests the possibility of development of targeted drugs effective not only against tumor cells but also against tumor stroma.
KEY WORDS: fibroblasts, glioma, apoptotic bodies, ganglioside GD2, antigen A2B5, tumor-associated fibroblasts, antibody–drug conjugate

DOI: 10.1134/S0006297925602631

Publisher’s Note. Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.